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Abstract 
Aim: 
To determine the trends of oxytocin use at a population level within New South Wales and to 
assess the maternal and neonatal morbidities associated with the use of oxytocin. 
Methods: 
Trends in oxytocin use were assessed for women in NSW who were nulliparas at term with a 
singleton, cephalic baby between 1998 and 2008. Maternal and neonatal morbidities were 
assessed in 2007-2008 using linked hospital and birth data with regression analysis. 
Oxytocin was also assessed by indication for use being either induction or augmentation of 
labour. 
Results:  
The overall use of oxytocin increased from 10,291 (36.5%) of births in 1998 to 14,440 
(45.4%) of births in 2008 (p<0.0001) with the increase entirely due to the increased use for 
induction of labour. The use of oxytocin was associated with an increase in regional 
analgesia (65 to 22%), instrumental delivery (21 to 18%) and caesarean section (29 to 14%) 
as compared to women who did not receive oxytocin in labour. Oxytocin was also associated 
with an increase in severe maternal (aOR 1.48, 95% CI 1.30 to 1.68) and neonatal morbidity 
(aOR 1.29, 95% CI 1.17 to 1.41). This increase in morbidity was maintained when both 
augmentation and induction were assessed separately 
Conclusion: 
Oxytocin has an important role in the management of labour. However its use should be  
carefully monitored with standardised treatment regimes to minimise maternal and neonatal 
morbidity.  
4 
 
Keywords: Oxytocin, Labour obstetric, Labour induced, Maternal morbidity, Neonatal 
morbidity
5 
 
Introduction 
Oxytocin is the commonest pharmacological agent used to either induce or augment labour. 
The role of endogenous oxytocin in labour is unclear but is thought to relate to oxytocin 
stimulating prostaglandin release within the uterus resulting in contraction of the uterine 
myometrium (1, 2). 
 
Administration of oxytocin can be associated with complications such as uterine 
hyperstimulation and injudicious use of oxytocin has the potential to increase fetal hypoxia 
and acidosis and thereby result in adverse neonatal outcome (3-5). Oxytocin is the 
medication most commonly associated with preventable adverse neonatal outcome 
prompting recent concern about its use. In the United States this concern has resulted in 
oxytocin being added by the Institute for Safe Medication Practices to a list of medications 
"bearing a heightened risk of harm"(6). In addition the Food and Drug administration in the 
USA have placed a warning on oxytocin stating that the medication should be restricted to 
medically indicated inductions or augmentations and should not be used for elective 
induction of labour (7). With such concerns raised regarding the use of oxytocin, the aims of 
this study were to determine trends in oxytocin use at a population level. We also 
investigated whether oxytocin was a risk factor for neonatal and maternal morbidity, 
regardless of the context of use (induction or augmentation of labour). 
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Methods 
The study population included nulliparous women attempting labour with a singleton, 
cephalic presenting fetus at term (370 to 416 weeks gestation) in NSW. The study was 
restricted to nulliparous women because of the different risk profiles and confounding of 
subsequent pregnancies by previous pregnancy. Exclusions were infants and their mothers 
with major congenital anomalies, stillbirths and those undergoing pre-labour caesarean 
section.  
 
Data were obtained from two population datasets, ‘birth data’ from the NSW Midwives Data 
Collection (MDC), and ‘hospital data’ (for both the mother and the baby) related to the birth 
from the NSW Admitted Patients Data Collection (APDC). The MDC is a statutory 
population-based collection covering all births in NSW of at least 400 grams birth weight, or 
at least 20 weeks gestation, and includes information on maternal and infant characteristics, 
pregnancy, labour, delivery, and condition of the infant. The APDC is a census of all 
admissions in NSW public and private hospitals. Up to 20 diagnosis and procedures for each 
separation are coded according to the 10th revision of the International Classification of 
Diseases, Australian Modification (ICD-10-AM) and the Australian Classification of Health 
Interventions (ACHI). The NSW Centre for Health Record Linkage performed probabilistic 
data linkage between the two datasets. Linkage proportions were over 98%. Ethical approval 
was obtained from the NSW Population and Health Services Research Ethics Committee. 
 
The primary outcomes considered were severe neonatal and maternal morbidity. We used 
composite indicators, the neonatal adverse outcome indicator (NAOI) and maternal morbidity 
outcome indicator (MMOI), which have been developed for use, and validated in, population 
health data.(8, 9)  Consistent with the method used by the World Health Organisation,(10) 
the indicators incorporate both disease-specific (e.g. respiratory distress, cardiac failure) and 
management-based (ventilation, transfusion) criteria (see Appendix 1 for complete list).(8, 9) 
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Composite indicators, that incorporate both diagnoses and procedures, overcome the 
problem of under-ascertainment of individual adverse events and reduce the need to rely on 
single ICD codes that have limited clinical detail, lack clear definitions or are poorly 
validated.(9)  
 
Oxytocin and prostaglandin use were defined as any record (in the birth data or hospital 
data) of use of either drug for induction or augmentation of labour. For labour inductions, a 
10-item check box is used to report the indication for induction. A woman was considered to 
have received regional analgesia for labour if either an epidural/caudal or a combined spinal-
epidural was recorded in the birth data. Maternal and neonatal characteristics were taken 
from the birth data, and hypertension and diabetes from either the birth or hospital data. 
Hospitals were grouped on the basis of similar rates of oxytocin use. Infant birth weight was 
classified as small or large for gestational age if it is below the 10th percentile or above the 
90th percentile for gestational age, respectively. 
 
Population trends in oxytocin use were determined for all pimipara at term from 1998 to 
2008, inclusive.  To investigate the effect of recent practices in oxytocin use on health 
outcomes, analyses were limited to 2007-2008 and to women who had the potential to be 
exposed to intrapartum oxytocin (i.e. births in midwifery lead units and homebirths were 
excluded). The association between oxytocin and adverse outcomes was assessed both 
overall, and (to explore any confounding by indication) separately among ‘low risk’ women, 
and women with hypertension. Low risk women were those without medical conditions who 
delivered a single, live-born infant of average size (10-90th birth weight for gestational age 
percentile) at 39-41 weeks gestation (when adverse outcomes are at their nadir) and, if 
labour was induced, where the indication was reported as ‘other’. The hypertension analysis 
included women with chronic hypertension, gestational hypertension or preeclampsia from 
either birth or hospital data. 
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Analysis 
Trends in oxytocin use were assessed by negative binomial regression. To examine the 
predictors of severe neonatal and maternal morbidity, separate logistic regressions were 
performed.  The effect of oxytocin use was examined both overall and by augmentation and 
induction.. Explanatory variables which were significant at P<0.2 were entered into a logistic 
regression model, and the least significant removed in a stepwise manner until only 
variables significant at p<0.05 by the likelihood ratio test remained. Results are expressed 
as adjusted odds ratios (aOR) and 95% CI. Analyses were conducted in SAS, version 9.1 
(SAS Institute, Cary NC, USA).  
 
Results 
From 1998 to 2008, inclusive, 322,640 nulliparous women gave birth at term in NSW. The 
overall use of oxytocin among these women increased from 10,291 (36.5%) in 1998 to 
14,440 (45.4%) in 2008 (trend p<0.0001) with the increase entirely due to increased use for 
induction of labour 17.6% in 1998 to 26.2% in 2008 (trend p<0.0001) (Figure 1). Oxytocin 
use for augmentation declined to 2003, but then returned to a rate of 19% as it was in 1998. 
 
In the period 2007 to 2008, 61,227 nulliparous women gave birth in hospitals that use 
oxytocin for labour management.  Of these, 48.5% received oxytocin to induce (28.2%) or 
augment (20.3%) labour. Compared with women who did not receive oxytocin during labour, 
women receiving oxytocin were older (median age 29.4 vs. 28.0 years), and more likely to 
have hypertension and/or diabetes (Table 1). Use of regional analgesia during labour was 
higher in women receiving oxytocin (65.3% vs. 22.3%) (Table 1), with the majority of this 
being use of epidurals (63.4% vs. 20.7%). Caesarean delivery was more common among 
women receiving oxytocin (29.4% vs. 14.2%). 
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Overall, 2,223 (3.6%) newborns suffered severe morbidity (4.3% among those exposed to 
oxytocin vs. 3.0% in the unexposed, crude OR 1.46 (95% CI 1.34, 1.59)), while 1,025 (1.7%) 
mothers suffered severe morbidity (2.1% and 1.3% respectively, crude OR 1.57 (95% CI 
1.39, 1.78)). After adjustment for confounders, oxytocin was associated with neonatal 
morbidity overall, and the increase in risk (~30%) was similar for oxytocin use in both 
induction and augmentation (Table 2). A similar pattern was observed when the analysis 
was restricted to low risk women and women with hypertension. Oxytocin use was also 
associated with increased risk of maternal morbidity overall, with a higher point estimate 
associated with oxytocin for induction (aOR=1.54) than augmentation (aOR=1.38) although 
the confidence intervals overlap (Table 2). The low risk and hypertension subgroup analyses 
for maternal morbidity, found somewhat attenuated and more similar ORs for induction and 
augmentation, although most did not reach statistical significance (Table 2). When analysed 
as any oxytocin use the risk for maternal morbidity was increased in hypertensive women by 
34% and in low risk women was increased by 28% (Table 2) 
 
Discussion  
Our study demonstrates that since 1998 there has been a sustained and significant increase 
in the use of oxytocin in NSW for nulliparas at term. For the most recent years available 
nearly half of all such women attempting labour received oxytocin. This usage was 
associated with an increase in both maternal and neonatal morbidity regardless of whether 
the indication for use was induction or augmentation of labour. Even for low risk nulliparous 
women at term there was an increase in both maternal and neonatal morbidity associated 
with oxytocin. For newborns at term, there was an absolute increase in severe morbidity risk 
from 3.0% to 4.3% and for mothers from 1.3% to 2.1%. With almost 270,000 women 
delivering at term in Australia (11), these increases translate to a significant burden for 
families and health resources.  
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Adverse effects associated with oxytocin use have been widely reported, are implicated in 
professional liability claims and are almost exclusively mediated through its dose-related 
effects on uterine activity (6, 7). Although some clinical trials with strict patient selection 
criteria and tightly run protocols have not found an increased risk of adverse perinatal 
outcomes, (12-15) these benefits are not observed when extended to a broader population 
without strict administration protocols. A strength of this study is the use of validated, 
population data that allow examination of the birthing experience for an entire population, 
incorporating all the variations in practice around the use of oxytocin and allowing 
assessment of rare outcomes. Few other population studies have information on the type of 
drug used and have been unable to differentiate induction and augmentation. A notable 
exception is a population-based study from Sweden which assessed the use of oxytocin in 
labour and also reported an increased risk of adverse neonatal outcomes (apgar score <7 at 
5 minutes (OR 2.3, 95% CI 1.8-29), umbilical arterial pH <7.05 (OR 2.9, 95% CI 2.0-2.7) 
NICU admission (OR 1.6, 95% CI 1.5-1.7)). When assessing maternal outcomes there was 
an increase in the use of epidural analgesia and caesarean section for women receiving 
oxytocin. However, other significant maternal morbidities were not reported (16). 
 
We think that our data reflect a change in decision making by caregivers. Our findings 
suggest that the morbidity associated with oxytocin is not a result of pathology that requires 
its use but an independent effect of its large and indiscriminate use. Risk of adverse 
outcomes were increased even among low risk women. It is well recognised internationally 
that there is considerable variation in practice with respect to method of oxytocin 
administration, dosage, infusion protocols, and maximal dose administered. (2, 7, 17-19). 
There is also no consistency in practice with respect to whether oxytocin is ceased once 
labour is initiated or in the duration of oxytocin use before caesarean section is considered 
for either failed induction of labour or prolonged labour (20). It has been observed but not 
quantified that such practice variations also occur in Australia. With the concerns raised 
regarding the use of oxytocin, both for induction and augmentation of labour, it is imperative 
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that standardised regimes are developed and implemented to help minimise maternal and 
fetal complications (7, 21, 22). 
 
Several limitations need to be borne in mind when interpreting the results of our study. First, 
despite our best efforts to adjust for risk factors, the results may be subject to residual 
confounding such that the adverse outcomes in-part reflect the reason for intervention rather 
than its consequence. However, the consistency of the estimate of risk (increased by 
approximately 30% across risk strata including low risk women) and irrespective of the use 
of oxytocin for induction or augmentation argues in favour of a true effect. Second, detailed 
clinical information was not available including the dose and duration of oxytocin infusion, 
duration of labour and the severity of the associated medical problems. Both a prolonged 
latent stage and a prolonged first stage of labour are associated with adverse maternal and 
neonatal outcomes (23). Third, only a single indication for induction is collected. And finally, 
it is unclear whether use of oxytocin in the management of prelabour ruptured membranes at 
term is recorded as induction or augmentation of labour and this may vary between 
hospitals. And finally,  
 
The increase in oxytocin use observed in NSW was primarily due to the use of oxytocin for 
induction of labour, which increased by 49%. This finding of an increase in rates of induction 
of labour has also been reported in the UK, USA and Canada (24-28), but has not translated 
into improvements in maternal or neonatal outcomes (28-30). Also of note is the doubling of 
the caesarean section rate among women exposed to oxytocin (29%) compared to those 
who did not receive oxytocin (14%). Therefore the clinical indication and need for oxytocin 
induction should be considered carefully and balanced against the potential harms 
associated with its use when considering planned elective delivery. 
 
In conclusion oxytocin has an integral role in the management of labour. However, it remains 
a potentially dangerous drug. The use of oxytocin should be carefully monitored with a 
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standardised treatment regimen to minimise maternal and neonatal adverse outcomes. 
Further research is required within Australia to determine the variations in obstetric practice 
with regard the use of oxytocin.  
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Figure 1: Trend in use of oxytocin among nullipara at term (37-41 weeks, 1998-2008) 
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Table 1 Maternal and birth characteristics by oxytocin usage 
    
    Oxytocin 
N=29711 
N (%) 
No Oxytocin 
N=31516 
N (%) 
Maternal Age   
 <20 1557 ( 5.2) 3045 ( 9.7) 
 20-34 27530 ( 92.7) 27972 ( 88.8) 
 35+ 623 ( 2.1) 499 ( 1.6) 
Maternal Smoking   
 Yes 2539 ( 8.5) 3833 ( 12.2) 
Hypertension   
 Any 4297 ( 14.5) 3027 ( 9.6) 
Diabetes   
 Any 2098 ( 7.1) 1389 ( 4.4) 
Hospital Level   
 Tertiary obstetric 13843 ( 46.6) 12925 ( 41.0) 
 Small/Medium 3382 ( 11.4) 6507 ( 20.6) 
 Large 4500 ( 15.1) 5411 ( 17.2) 
 Private 7986 ( 26.9) 6673 ( 21.2) 
Gestational Age   
 37 1430 ( 4.8) 1793 ( 5.7) 
 38 3808 ( 12.8) 4415 ( 14.0) 
 39 6743 ( 22.7) 8318 ( 26.4) 
 40 9948 ( 33.5) 11323 ( 35.9) 
 41 7782 ( 26.2) 5667 ( 18.0) 
Birth weight percentile   
 0.0-9.9 2867 ( 9.6) 3827 ( 12.1) 
 10.0 - 90.0 24025 (80.9) 25724 (81.7) 
 90.1 - 100 2805 ( 9.4) 1944 ( 6.2) 
Regional Analgesia   
 Yes 19414 ( 65.3) 7035 (22.3) 
Onset of labour   
 Spontaneous 
(augmentation) 
12437 ( 41.9) 25884 ( 82.1) 
 Induction 17274 ( 58.1) 5632 ( 17.9) 
Prostaglandin   
 Yes 7222 ( 24.3) 4562 ( 14.5) 
ARM   
 Yes 16966 ( 57.1) 9334 ( 29.6) 
Mode of delivery   
 Normal vaginal  11651 ( 39.2) 21445 ( 68.0) 
 Instrumental 9337 ( 31.4) 5609 ( 17.8) 
 Caesarean 8723 ( 29.4) 4462 ( 14.2) 
*Referent group is not having the exposure, unless otherwise stated
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Table 2 Adjusted odds ratio for effect of oxytocin use on neonatal and maternal morbidity, 2007-2008 
 Oxytocin Neonatal morbidity Maternal morbidity 
  Adjusted 
OR* 
95% CI Adjusted 
OR* 
95% CI 
Overall      
N=61227 Augmentation 1.26 ( 1.12, 1.42) 1.38  (1.18,1.63)  
 Induction 1.31 (1.18,  1.46) 1.54 (1.35,1.78) 
      
 Any Oxytocin† 
 
1.29 (1.17,1.41) 1.48 (1.30,1.68) 
Hypertension      
N=5172 Augmentation 1.21  (0.85,1.73) 1.28 (0.79,2.07) 
 Induction 1.34 (1.01,1.78) 1.37 (0.93,2.02) 
      
 Any Oxytocin† 
 
1.30 (1.00,1.68) 1.34 (0.94,1.91) 
Low Risk Women      
N=24499 Augmentation 1.36 (1.16,1.60) 1.30 (1.03,1.65) 
 Induction 1.44 (1.14,1.82) 1.22 (0.86,1.73) 
      
 Any Oxytocin† 
 
1.38 (1.19,1.60) 1.28 (1.03,1.60) 
 
* Referent group is no oxytocin. ORs are adjusted for factors with in Table 1. 
† Oxytocin use for either augmentation or induction 
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Appendix 1.  Components of neonatal adverse outcome indicator (NAOI) and maternal 
morbidity outcome indicator (MMOI) (8, 9) 
 
Neonatal adverse outcome indicator Maternal morbidity outcome indicator 
Diagnoses  
Birth trauma (intracranial haemorrhage 
paralysis due to brachial plexus injury, skull 
or long bone fracture) 
Acute abdomen 
Birthweight < 1,500 g Acute renal failure 
Broncho-pulmonary dysplasia Acute psychosis 
Cerebral infarction Cardiac arrest, failure or infarction 
Death (before discharge home) Cerebral oedema or coma 
Gestational age < 32 weeks Disseminated intravascular coagulopathy 
Hypoxic ischemic encephalopathy Cerebro-vascular accident 
Intraventricular haemorrhage (grades 2-4) Major complications of anaesthesia 
Necrotising enterocolitis Obstetric embolism 
Other respiratory: primary atelectasis, 
respiratory failure 
Shock 
Periventricular leukomalacia Sickle cell anaemia with crisis 
Pneumonia Status asthmaticus 
Respiratory distress syndrome Status epilepticus 
Seizure Uterine rupture 
Sepsis/ septicaemia (streptococcus, 
staphylococcus, E. coli, unspecified Gram-
negative) 
 
Procedures  
Any body cavity surgical procedure Assisted ventilation including tracheostomy 
Any intravenous fluids Curettage in combination with a general 
anaesthetic 
Central venous or arterial catheter Dialysis 
Pneumothorax requiring an intercostal 
catheter 
Evacuation of haematoma 
Resuscitation Hysterectomy 
Transfusion of blood or blood products Procedures to reduce blood flow to uterus 
Ventilatory support (mechanical ventilation 
and/or continuous positive airway pressure) 
Reclosure of disrupted Caesarean section 
wound 
 Repair of bladder or cystostomy 
 Repair of intestine 
 Repair ruptured or inverted uterus 
 Transfusion of blood or coagulation factors 
 
 
